RZ-001 Dose 3

DRUG2 trials

Sponsors

Rznomics, Inc.

Conditions

Hepatocellular CarcinomaHepatocellular Carcinoma (HCC)

Phase 1

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma

Active, not recruitingNCT05595473

Rznomics, Inc.Hepatocellular Carcinoma

Start: 2022-07-29End: 2029-05-31Target: 42Updated: 2024-11-04

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

RecruitingNCT06695026

Rznomics, Inc.Hepatocellular Carcinoma (HCC)

Start: 2024-12-18End: 2027-10-31Target: 45Updated: 2025-07-29